MiyoSmart® DIMS:
Defocus Incorporated Multiple Segments

MiyoSmart is a Hoya spectacle lens using DIMS technology. Published in The Lancet in 2020, it has some of the most robust evidence of any myopia control spectacle lens — including a Lancet publication, competitive efficacy, and no minimum age restriction.

52%

Axial length reduction vs single-vision control (Lam et al. Lancet 2020)

62%

Refractive progression reduction at 2 years (Lam 2020)

age 6+

No minimum age — suitable from school age onset

What is MiyoSmart DIMS?

MiyoSmart (Hoya) uses Defocus Incorporated Multiple Segments (DIMS) technology. The lens consists of a central optical zone for clear distance correction (9.4mm diameter), surrounded by 396 evenly distributed +3.50D defocus segments (each 1.03mm) extending to a 33mm treatment zone. The defocus segments impose myopic defocus on the mid-peripheral retina during all viewing tasks, thought to inhibit axial elongation via retinal dopamine signalling.

The Lancet RCT (Lam et al. 2020)

The pivotal RCT enrolled 183 Chinese children aged 8–13 in Hong Kong. At 2 years, children wearing MiyoSmart had:

52% less axial elongation than single-vision controls (0.41mm vs 0.85mm)
62% less refractive progression (−0.38D vs −1.00D)
21% of MiyoSmart children had no myopia progression at all vs 7% of controls
No significant adverse events; visual acuity equivalent to single-vision lenses

Why The Lancet matters: Most myopia control RCTs are published in ophthalmology subspecialty journals. A Lancet publication signals the trial met a higher threshold of methodological scrutiny and general medical significance. The DIMS trial is the only spectacle lens myopia control RCT published in a general medical journal of this tier.

DIMS vs Stellest: how the mechanisms compare

Feature	MiyoSmart DIMS	Stellest® HALT
Mechanism	396 × +3.50D defocus segments	Highly Aspherical Lenslet array (+3.50D)
Treatment zone	33mm diameter ring zone	11mm central + lenslet zone
Efficacy (AL)	52% (Lam 2020)	67% FTW / ~51% ITT (Bao 2022)
RCT journal	The Lancet	JAMA Ophthalmology
Population	Chinese children	Chinese children
Minimum age	No restriction	No restriction
FDA status	Not FDA approved (US)	Not FDA approved (US)
Compliance	Standard glasses wear	≥12 hrs/day for full effect

MiyoSmart vs MiSight: when each is appropriate

Choose MiyoSmart when the child is under 8, not ready for contact lenses, or parents prefer spectacle correction
Choose MiSight when the child is ≥8, willing to handle daily disposable lenses, and prefers glasses-free vision for sport
Choose Stellest when MiyoSmart is unavailable in your region or you prefer the HALT optical design

Availability

MiyoSmart is available in the UK, Europe, Australia, Hong Kong, Singapore, and many other markets. It is not available in the US. Clinicians in the US are limited to MiSight (FDA-approved), orthokeratology, or off-label atropine for myopia control.

All Treatments

9 Treatments Ranked

MiyoSmart in context — all modalities compared by AL reduction efficacy.

Comparison

MiSight® vs Stellest®

Deep-dive comparison of the two most prescribed optical modalities.

Contact Lens

MiSight 1 Day — Full Evidence

FDA-approved MiSight: 3-year and 6-year RCT data reviewed.

Rankings

Best Myopia Treatments (2026)

All modalities ranked with primary RCT source for each figure.

Combination

Add Atropine to MiyoSmart?

Combination therapy evidence for high-risk patients on spectacle lenses.

Calculator

Project MiyoSmart Outcomes

See projected AL at 18 with DIMS vs all other modalities.

Compare MiyoSmart for your patient

Enter age + axial length to see all 9 treatments projected side-by-side. Free, no login required.

Open Calculator →

Lam CSY et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression. Lancet. 2020;396(10240):70–77. doi:10.1016/S0140-6736(20)30560-5 · IMI 2025 Digest (Tahhan N et al.) · MiyoSmart® is a registered trademark of Hoya Corporation. This page is educational — not prescribing guidance.

MiyoSmart® DIMS:Defocus Incorporated Multiple Segments